Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,201–2,300 of 3,704
Commercially Available Injectables in Diabetes – Insulin, Incretins, and More
Kesavadev, J., Kalra, S., John, M., Unnikrishnan, A., Joshi, S., Sankar, P., Kumar, A., Jothydev, K., & Basanth, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_29_23 · Cited by 3
Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians
Grech, V.-S., Lotsaris, K., Grech, I., Kefala, V., & Rallis, E. A. (2024) · Review of Clinical Pharmacology and Pharmacokinetics - International Edition · doi:10.61873/rjdb1796 · Cited by 2
Key messages on obesity care from the 2023 ASPEN Physician Preconference Course: A narrative review
Basishvili, G., Newberry, C. A., Mechanick, J. I., Barazzoni, R., & Hennessy, S. A. (2024) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2632 · Cited by 1
Subbaiah, M. A. M., Mandal, U., Patankar, V., Bhaskaran, S., Nutakki, R., Bhadresh, R., Shah, D., Mahammad, S., Murphy, B. J., Huang, C., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116686 · Cited by 1
Small Bowel Therapies for Metabolic Disease and Obesity
Boškoski, I., Gualtieri, L., & Matteo, M. V. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.002 · Cited by 1
Srour, L., Ismail, J., Njeim, R., & Eid, A. A. (2024) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-62131-4_8 · Cited by 2
Weekly Journal Scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea
Liuzzo, G., & Patrono, C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae568 · Cited by 1
Demographic Data, Risk Factors, and Disease Burden of HS Patients in Lithuania at a Reference Center
Raudonis, T., Šakaitytė, A., Vileikis, T. P., Černel, V., Gancevičienė, R., & Zouboulis, C. C. (2024) · Healthcare · doi:10.3390/healthcare12181849 · Cited by 1
“Male patients exhibited a statistically significant tendency to experience intermittent pain more frequently.”
BackgroundManagement of cardiometabolic diseases: A clinician's perspective
Bassi, N. S., Mohan, P., & Itchhaporia, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00002-4 · Cited by 1
Putting metabolism centre stage in health and disease
Montgomery, M. K. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00032-3 · Cited by 1
GLP-1 and GIP analogues in the treatment of obesity
Jasińska-Balwierz, A., Balwierz, R. J., Biernat, P., Makieieva, N., Tomków, M., Cesarz, K., Osowski, M., Dorożyński, B., Skotnicka-Graca, U., & Lipok, J. (2024) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2024.0023 · Cited by 2
Healthcare utilization associated with obesity management in Ontario, Canada
Wharton, S., Belloum, A., Luckevich, M., Kamran, E., Luguzis, A., Eberg, M., KUKASWADIA, A. A., Neish, C. S., Capucci, S., Varbo, A., et al. (2024) · Clinical Obesity · doi:10.1111/cob.12720 · Cited by 3
“23 Recent studies have shown that pharmacotherapy for obesity has improved outcomes for those living with obesity, 24,25 which may further impact costs associated with obesity-related complications.”
Self-citationManagement of Obesity in Bangladesh – Position Statement of Bangladesh Endocrine Society
Haq, T., Robel, M. A. B., Kobra, T., Karim, M. R., Ahammed, A., Mahjabeen, S., Sarkar, S., Tanni, A. Z., Hossain, T., Mustari, M., et al. (2024) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_35_24 · Cited by 2
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Zhou, Y.-F., Li, Q., Wang, L.-G., Lu, Y., Wang, Y., & Yang, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00041-w · Cited by 1
A Rare Case of Tirzepatide-Induced Hepatitis: Causality Assessment With the RUCAM Criteria
Ahmed, R. T., Almatrooshi, C. A., AlShehhi, S. J., & Bakri, M. T. (2025) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2024.0923 · Cited by 4
Psychopharmakainduzierte Gewichtszunahme – sind Inkretine/Twinkretine eine Option?
Paulzen, M. (2025) · Der Nervenarzt · doi:10.1007/s00115-024-01788-1 · Cited by 3
“In der sogenannten SURMOUNT-1-Studie zeigte Tirzepatid substanzielle Gewichts-abnahmen bei Patienten mit Adipositas [19].”
Arvate, H. R. (2025) · International Journal of Nutrology · doi:10.54448/ijn25102 · Cited by 1
Grudén, S., Forslund, A. H., Litorp, H., et al. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1503 · Cited by 1
“Assay: analytical range: 10.0-250 mg triolein/g feces; sample amount: 15.0 g homogenate (feces:UPW [1:2] corresponding to 5.0 g of feces); matrix: human feces.”
InfluentialLow Molecular-Mass Hormones: Peptidic and Steroidal Hormones
Gelves, L. G. V., Trindade, A. C. L. B., & Lima, L. M. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_176 · Cited by 2
Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity: A Clinical Review
Overholser, A., Czech, E. J., Speer, L., Wilson, J., & Overholser, A. (2025) · Translation The University of Toledo Journal of Medical Sciences · doi:10.46570/utjms-2024-1218 · Cited by 2
Piťhová, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.009 · Cited by 1
Shadbolt, C., & Dowsey, M. M. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.02.779 · Cited by 2
Maki, K. C., Kirkpatrick, C. F., & Almandoz, J. P. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.019 · Cited by 1
Zhang, J., Wang, C., Wang, J., Gu, W., Wang, H., Zhu, H., Ma, X., & Shi, Z. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05664-9 · Cited by 1
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) including semaglutide and tirzepatide are effective and safe options for type 2 diabetes (T2DM) and weight control by stimulating delaying gastric emptying and decreasing appetite [12–15].”
Person Centered Approach and Challenges in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_7 · Cited by 4
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
FDG PET/CT Images Demonstrating Subclinical Pancreatitis in a Patient on a GLP-1 Receptor Agonist
Lenkov, R., Berman, T., Mehmi, I., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005856 · Cited by 1
The relationship between cholecystokinin and gastrin
Rehfeld, J. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23720-1.00014-9 · Cited by 1
Grenet, G., Gougeon, A., Salzwedel, D. M., Jauca, C. D., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016144 · Cited by 3
Obesity and Hypertension: Etiology and the Effects of Diet, Bariatric Surgery, and Antiobesity Drugs
Elattar, S., Chand, S., Salem, A. M., Abdulfattah, A., Bassiony, M. A. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000937 · Cited by 2
Dosing Exercise to Regulate Cardiometabolic Risk Among People Requiring Cardiac Rehabilitation
Gordon, B. A., Parr, E. B., & Schultz, M. G. (2025) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000361 · Cited by 1
Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity
Fitch, A. (2025) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2025.100621 · Cited by 3
“42,43 44-49 However, only 2% of patients with an indication for treatment have used AOMs.”
Brož, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.026 · Cited by 1
Animal models for development of anti-obesity drugs in the age of GLP-1 agents
Culver, A. E., Stayrook, K. R., Comerota, M. M., Oblak, A. L., & Burris, T. P. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2507766 · Cited by 2
“Similarly, humanized gastric inhibitory polypeptide receptor (GIPR) mouse models have emerged as critical tools, particularly in the context of dual (e.g. tirzepatide) and triple (e.g. retatrutide) incretin modulator drug development with prolific anti-obesity efficacy [20,21].”
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Pott, J., Kirchner, M., Hennigs, J. K., Sinning, C., Klose, H. F. E., & Harbaum, L. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70103 · Cited by 1
Ordemann, J., & Elbelt, U. (2025) · Herz · doi:10.1007/s00059-025-05319-9 · Cited by 1
“Auch führen die postoperativen Veränderungen in der Darmflora zu einer Modifikation der Kör-pergewichtsregulation und des Energie-stoffwechsels.”
Variations in weight loss and glycemic outcomes after sleeve gastrectomy by race and ethnicity
Vanegas, S. M., Curado, S., Zhou, B., Illenberger, N., Merriwether, E. N., Armijos, E., Schmidt, A. M., Ren‐Fielding, C. J., Parikh, M., Elbel, B. D., et al. (2025) · Obesity · doi:10.1002/oby.24320 · Cited by 3
“Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, results in (cid:1) 15% weight loss, whereas dual-incretin therapy with tirzepatide has demonstrated weight loss of (cid:1) 20% [4 – 9].”
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Ding, H., Wang, M., Zhang, J., Wan, C., Huang, Z., Liu, L., & Liu, J. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00174.2025 · Cited by 5
Corbalan, J. J., Petronella, B. A., Huang, C., Beasley, J. R., Merritt, J. R., Mugrage, B., & Nickels, J. T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152360 · Cited by 1
Misra, S., Narayan, R. K., & Kaur, M. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0113 · Cited by 3
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Current and Future Implications of Weight Loss Drugs on Liver Disease
Bussetty, A., Shah, N., Chandler, T. M., Ghattu, M., & Kesavarapu, K. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.005 · Cited by 1
Bombassaro, B., Batitucci, G., Simoes, M. R., ARAUJO, E. P. D., & Velloso, L. A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1626068 · Cited by 4
“In clinical trials, body mass reductions approached the magnitude previously achieved by bariatric surgery, only (115).”
Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. H. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03288-3 · Cited by 3
“…SURMOUNT-1 trial and the licensed population for both tirzepatide and liraglutide in weight management, with baseline characteristics sourced from the SUR-MOUNT-1 patient population, or from published literature, where required (see Tables S2 and S3 in the supplementary materials) [10, 11, 14–19].”
InfluentialYang, F., Zhou, L., Zhang, J., Wang, Q., Cai, Q., Wang, J., Wu, C., Li, X., Zhang, J., Zheng, Y., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003156 · Cited by 1
Kasagga, A., Rebellow, D., Hashmi, T., Husami, M. Y., Lama, P., Selvan, K., & Nakasagga, K. (2025) · Cureus · doi:10.7759/cureus.90335 · Cited by 13
Alabadí, B., Amores, S., Moriana, M., Xiong, N. Y. W., García-Malpartida, K., Pedrón, J. A., Monrós, C., Martínez‐Hervás, S., Real, J. T., & Civera, M. (2025) · Life · doi:10.3390/life15081300 · Cited by 1
“Nevertheless, physical-function scores improve, even with substantial weight reduction, indirectly suggesting that MSS may improve after treatment despite the decrease in muscle mass [30–32].”
Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea
Qian, B., Huang, Y., Yan, C. X., Feng, S., & She, D. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70090 · Cited by 1
“Originally developed for glycemic control in T2DM, these agents have demonstrated substantial weight reducing effects [23, 24].”
The Role of Insulin Sensitivity in Lean Mass Changes During Weight Loss With or Without Exercise
Bartholomew, C. L., Martins, C., & Gower, B. A. (2025) · Obesity · doi:10.1002/oby.70010 · Cited by 1
A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy
Lee, S. M. (2025) · Current Drug Targets · doi:10.2174/0113894501398624250819070004 · Cited by 2
Evaluation and Management of Obesity Hypoventilation Syndrome in Ambulatory and Hospital Settings
Neborak, J. M., & Mokhlesi, B. (2025) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2025.07.008 · Cited by 1
Ibsen, D. B., Kobayashi, R., Bruun, J. M., & Drouin‐Chartier, J. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.07.040 · Cited by 1
Current trends in bariatric surgery
Неймарк, А. Е., & Lapshina, S. E. (2025) · Russian surgical journal · doi:10.18705/3034-7270-2025-1-2-103-111 · Cited by 1
Sathiavageesan, S., Sundaram, V., & Kurien, A. A. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf153 · Cited by 1
Kloock, S., Scheller, L., Hasinger, J., Balonov, I., Kurlbaum, M., Faßnacht, M., Koschker, A., Seyfried, F., & Dischinger, U. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112923 · Cited by 2
Walton, S., Guirguis, E. H., Mack, K., & Assil, R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf251 · Cited by 1
Gradually, then Suddenly: Nutrition in an Era of Medically Induced Weight Loss
Bergia, R. E., Davis, E. M., & Campbell, W. W. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.09.033 · Cited by 1
ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine
Russo, S. L. M. L., Proto, L., Neto, M. G., Angelini, G., Pezzica, S., Carli, F., Previti, E., Caristo, M. E., Bove, V., Chakaroun, R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70167 · Cited by 3
Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women
Mohammed, A., & Mishra, S. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.09.012 · Cited by 1
Malaikah, S., Alruwaili, A., Sanders, J. P., Thackray, A. E., Stensel, D. J., Thivel, D., Henson, J. J., Rowlands, A. V., Willis, S. A., & King, J. A. (2025) · Nutrients · doi:10.3390/nu17193163 · Cited by 1
“The clinical success of these agents [3,4] underscores the pivotal role of appetite in eating behaviour and body weight regulation.”
Rothberg, A. E., Ye, W., Miller, N., & Rizza, R. A. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70092 · Cited by 1
A Call to Action for Starting Clozapine: Increasing Clozapine Use and Safety in a Post-REMS Era
Leung, J. G., & Cotes, R. O. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250023 · Cited by 2
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
AGA Institute Quality Indicators for Obesity Medication Use in Practice
Newberry, C. A., Peng, F. B., Lynch, K. L., Sheth, S. G., Pickett‐Blakely, O., & Maratt, J. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.006 · Cited by 1
Friedman, O., & Tal, D. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012523 · Cited by 3
Reid, K. F., & Bhasin, S. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1640030 · Cited by 4
Tirzepatide: A Breakthrough Therapy for Obstructive Sleep Apnea and Metabolic Dysfunction
Singh, G., Jaswal, T., Kosey, S., Kumar, R., & Kaur, A. (2025) · Current Hypertension Reviews · doi:10.2174/0115734021398680251001102514 · Cited by 2
Food and the brain: Neural and endocrine control of feeding, metabolism, and reproduction
Mansano, N. D. S., Lieu, C. V., & Abizaid, A. B. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70104 · Cited by 4
“72,73 Notably, obesity has been linked with alterations in reproduction.”
Islam, T., & Uddin, M. N. (2025) · EMJ Diabetes · doi:10.33590/emjdiabet/rkyo7834 · Cited by 1
“33,34 GLP-1 receptor agonists facilitate weight loss and improve glycaemic control (as an established medication used for weight loss).”
From trend to treatment: Regulating anti-obesity medications in India
Shekha, T. A. M., & Suresh, S. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100661 · Cited by 1
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
Brennan, D. J., & Lynch, L. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0991 · Cited by 1
Hussain, M., & Miras, A. D. (2025) · Die Chirurgie · doi:10.1007/s00104-025-02402-z · Cited by 3
Renna, N. F., Ramirez, E. I., Arrupe, M. F., & Ramirez, J. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004158 · Cited by 1
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Thiriveedi, M., Domingo, F. S., Yates, H., Baddam, S., Beblawy, R. E., Nimmana, B., & Patel, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004055 · Cited by 8
“−24.8% 72 weeks 15 mg (weekly) Obesity (non-diabetic) SURMOUNT-1 [ 11 ] CRP reduction (”
InfluentialHossain, A., Fahim, M., Abdalla, M., Fozo, K., Mon, M., Botond, K., Veettil, S., Belgaumkar, A. P., & Carswell, K. A. (2025) · Cureus · doi:10.7759/cureus.96974 · Cited by 1
Mergulhão, A. O., Ribeiro, N. D., Paiva, P. L., Maciel, R. V., Junior, C. Q. D. L., de Sousa, M. C., Luniere, J. A., Almeida, F. M. D., Horbylon, A. J. G., Ghazale, P. P., et al. (2025) · Aracê. · doi:10.56238/arev7n11-226 · Cited by 1
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
Chi, H., Yang, H., & Deng, Y. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2513141 · Cited by 1
Challenges in Expanding the Donor Pool and Improving Long-Term Outcomes for Liver Transplantation
Ferrarese, A., Battistella, S., D’Arcangelo, F., Feltrin, G., Barbieri, S., Bassi, D., Zanetto, A., Germani, G., Russo, F. P., & Burra, P. (2025) · Archives of Medical Research · doi:10.1016/j.arcmed.2025.103348 · Cited by 1
Салухов, В. В., Борисович, Ш. С., & Petrankov, K. V. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-467 · Cited by 2
Frederiksen, K., Berger‐Fleishman, R., Jad, A., Mattar, S. G., & Shetye, B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100232 · Cited by 2
“Tirzepatide, approved in 2023 as Zepbound, goes even further, with average weight loss approaching 21% [20,21].”
Enteric microbiome and obesity: a multidimensional narrative review
Barat, B., Ghosh, K., Kulkarni, B. P., Banerjee, P., & Ghosh, K. (2025) · Microbial Genomics · doi:10.1099/mgen.0.001562 · Cited by 1
Duncan, J., Stevens, P. L., Bigby, E., Floyd, C., Malina, J., Nickens, J., Lambert, A., & Kantor, T. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100236 · Cited by 2
“Gastrointestinal issues like nausea, diarrhea, and constipation are the most frequently reported side effects of tirzepatide therapy [3,14].”
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
“In a large-scale RCT for obesity ( n = 2,539, 72-week follow-up), 95.3% of participants that received tirzepatide achieved normoglycemia (26), compared to 61.9% in the placebo group.”
InfluentialTirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
Sanchis‐Gomar, F., Neeland, I. J., Ruiz‐Lozano, P., Alnahar, O., & Rodríguez, F. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02334-4 · Cited by 1
“In the SURMOUNT-1 substudy [35, 38, 39], which evaluated tirzepatide versus placebo over 72 weeks in 160 participants (allocation details for semaglutide or placebo not reported), reported an average body weight reduction of 22.1 kg (-21.9%).”
InfluentialSaeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“A whop-ping 90% and 91% of participants on tirzepatide 10 or 15 mg lost ≥ 5% of body weight, compared to 35% on placebo [ 25].”
InfluentialCarrillo-Larco, R. M., Varghese, J. S., Quyyumi, A. A., Narayan, K. M. V., Wilson, P. W. F., & Ali, M. K. (2025) · International Journal of Hypertension · doi:10.1155/ijhy/7193567 · Cited by 1
“In addition, weight loss medications such as semaglutide and tirzepatide [34, 35], which are rapidly changing the paradigm of obesity treatment, may have important benefts for people with EOH.”
Bajpai, J., Saxena, M., Agarwal, U., & Pradhan, A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i4.109762 · Cited by 1
The dominant driver paradigm of cardiometabolic care
Sevillano, J. H., Babagoli, M. A., Chen, Y., Liu, S. H., Mellacheruvu, P., Johnson, J. G., Ibáñez, B., Lorenzo, Ó., & Mechanick, J. I. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101389 · Cited by 2
“Moreover, this is especially significant in this era in which there is availability of safe and effective pharmacological treatments for the management of abnormal adiposity, for patients unable to meet sufficient and/or sustained weight loss based on lifestyle measures alone [20].”
Jalan, A., Murzinski, E. S., Jansen, P. J., Miller, R. D., Embry, M. C., Scherer, R. B., Moomaw, J. F., Williams, K. M., Fisher, C. A., James, J., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202520060 · Cited by 2
Lee, A. T., Park, C. H., Arter, Z., Nagasaka, M., & Ou, S.-H. (2025) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s549011 · Cited by 1
“5,6 However, the efficacy and toxicities of these GLP-1 agonists in managing weight gain induced by ALK TKIs have been limited and incomplete at best.”
Sun, Y., Abed, M., & Sohouli, M. H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02071-2 · Cited by 1
“…in general obesity, the observed weight loss magnitude is somewhat lower than that achieved with GLP-1 receptor agonists or dual incretin therapies [23–26], yet remains clinically significant, especially for patients with genetically defined obesity who may have limited treat-ment options [27].”
Jamal, Z., Siddiqui, A., Haider, M. I., Alam, S., & Alam, I. (2026) · Journal of Robotic Surgery · doi:10.1007/s11701-025-03095-6 · Cited by 1
“Bariatric and metabolic surgery remains the most reliable intervention for achieving sustained weight loss and meta - bolic improvement, particularly in patients with severe and super-obesity (BMI ≥ 50 kg/m²), where it consistently out - performs non-surgical therapies [3– 6].”
Carpinelli, L., Amato, C., Marinelli, D. A., Stornaiuolo, G., & Savarese, G. (2026) · Obesities · doi:10.3390/obesities6010001 · Cited by 2
“Dual GLP-1/GIP receptor agonists such as tirzepatide have shown superior metabolic efficacy compared with semaglutide, and early pilot data suggest potential benefits for appetite control and emotional eating [35–37].”
Castaneda, R., Sepulveda, D., Gutiérrez, R. D. J. R., Villamarin, J. L., Bechenati, D., Espinosa, M. A., Verastegui, A., Tama, E., McNally, A. W., Bennett, P. K., et al. (2026) · Diabetology · doi:10.3390/diabetology7010010 · Cited by 1
“Pivotal clinical trials have shown that individuals without T2D achieve approximately 33% greater weight loss with tirzepatide (20% TBWL in individuals without T2D vs. 15% in those with T2D) following 72 weeks of treatment at a 15 mg weekly subcutaneous dose [8,9].”
Shi, L., Li, D., & Li, Y. (2026) · Medical Review · doi:10.1515/mr-2025-0048 · Cited by 3
Sraboni, A., & Farhana, K. M. (2026) · Journal of Biochemistry Pharmacology and Public Health · doi:10.64907/xkmf.v4.i1.jbpph.1 · Cited by 1
Güney, H. D., Akçay, N., Sofuoğlu, C., Kohl, M., & KEMMLER, W. K. (2026) · Applied Sciences · doi:10.3390/app16020742 · Cited by 1
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.